- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Valbiotis SAS (ALVAL)
The Valbiotis share price today is 0.840, view EPA ALVAL stock exchange data. Track the latest Valbiotis share price with real-time updates on ALVAL stock performance including market cap, day range, 52-week range and dividend yield. Access ALVAL charts, earnings dates and analyst estimates to support your investment decisions.
Paris
Currency in EUR
0.840
-0.016(-1.87%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.836
0.852
52 wk Range
0.535
1.296
ALVAL is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.8360.852
52 wk Range
0.5351.296
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ALVAL Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
1.800
Upside
+114.29%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales growth in the current year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Analyst Ratings
1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 1.800
(+114.29% Upside)
Earnings
Latest Release
02-03-2026
EPS / Forecast
-0.20 / --
Revenue / Forecast
572K / --
Compare ALVAL to Peers and Sector
Metrics to compare | ALVAL | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipALVALPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.2x | −3.2x | −0.3x | |
PEG Ratio | −0.09 | −0.06 | 0.00 | |
Price/Book | 2.9x | 1.6x | 2.6x | |
Price / LTM Sales | 22.4x | 19.4x | 3.1x | |
Upside (Analyst Target) | 110.3% | 126.8% | 49.0% | |
Fair Value Upside | Unlock | −1.2% | 6.3% | Unlock |
Valbiotis SA engages in the research and development of dietary supplements to prevent metabolic and cardiovascular diseases in France and Asia. The company offers supplements for immunity and vitality, health and wellbeing, metabolic and cardiovascular health, and beauty and physical comfort. It also develops TOTUM-63 for the reduction of fasting blood glucose and treatment of type 2 diabetes; TOTUM-854, which is in Phase II/III clinical trials for reducing systolic blood pressure; and TOTUM-448 for the reduction of hepatic steatosis. Additionally, the company offers e-commerce delivery service in Belgium and Luxembourg. Valbiotis SA was incorporated in 2014 and is based in Périgny, France.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Valbiotis (ALVAL) Share Price Today?
The Valbiotis share price today is 0.840.
What is the current Valbiotis (ALVAL) share price and day range?
As of 18-08-2026, the Valbiotis share price is 0.840, with a previous close of 0.856. The share price has ranged from 0.836 to 0.852 today, while the 52-week range spans from 0.535 to 1.296.
What Is the Valbiotis Market Cap?
As of today, Valbiotis market cap is 19.870M.
What Is the Valbiotis (ALVAL) Share Price Target?
The average 12-month share price target for Valbiotis is 1.800, with a high estimate of 1.8 and a low estimate of 1.8. 1 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +114.29% Upside potential.
What Is Valbiotis's Earnings Per Share (TTM)?
The Valbiotis EPS (TTM) is -0.475.
From a Technical Analysis Perspective, Is ALVAL a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
What Stock Exchange Does Valbiotis Trade On?
Valbiotis is listed and trades on the Paris Stock Exchange.
What Is the Stock Symbol for Valbiotis?
The stock symbol for Valbiotis is "ALVAL."
How Many Times Has Valbiotis Stock Split?
Valbiotis has split 1 times.
How Many Employees Does Valbiotis Have?
Valbiotis has 50 employees.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.